NovaBridge Biosciences (NBP) — Financial Flexibility Index
NovaBridge Biosciences (NBP) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of $13.15 Million (operating CF $13.15 Million minus capex $41.00) represents 0% of total liabilities ($131.67 Million). Check asset allocation strategy of NovaBridge Biosciences to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NovaBridge Biosciences Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for NovaBridge Biosciences across 8 annual periods. See NBP working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for NovaBridge Biosciences (2017–2024)
Year-by-year free cash flow to debt coverage for NovaBridge Biosciences. For the full company profile including market capitalisation, see NovaBridge Biosciences market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.57x | $-52.60 Million | $-52.65 Million | $11.52 Million | ▼ -5521.1% |
| 2023 | -0.08x | $-72.69 Million | $-72.85 Million | $894.81 Million | ▲ +91.8% |
| 2022 | -0.99x | $-1.06 Billion | $-1.10 Billion | $1.07 Billion | ▼ -9.6% |
| 2021 | -0.91x | $-943.16 Million | $-973.09 Million | $1.04 Billion | ▼ -244.9% |
| 2020 | 0.62x | $441.57 Million | $433.56 Million | $706.65 Million | ▲ +375.5% |
| 2019 | -0.23x | $-855.74 Million | $-867.98 Million | $3.77 Billion | ▼ -183.8% |
| 2018 | -0.08x | $-266.30 Million | $-280.70 Million | $3.33 Billion | ▲ +54.3% |
| 2017 | -0.17x | $-231.83 Million | $-252.16 Million | $1.33 Billion | — |